Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
INL4
- Development stage
- Preclinical
- Lead developer
- Innolife Pharma
- Modality
- Small Molecules
01
Overview
INL4 (also known as INL-4) is an investigational therapeutic candidate being developed by Innolife Pharma for the treatment of atherosclerosis. The drug is currently in the research and early preclinical stage of development. Innolife Pharma's pipeline focuses on the therapeutic application of trace elements and targeted drug delivery to stimulate tissue repair and organ regeneration. While specific mechanistic details and molecular targets for INL4 have not been fully disclosed, it is part of Innolife's broader program targeting cardiovascular diseases.
Beyond the preview
Go deeper on INL4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on INL4.